A creative and skilled scientist with over 13 years of experience developing analytical methods to measure pharmacokinetics, pharmacodynamics, biomarkers, and immunogenicity for the development of protein and small molecule therapeutics. I have contributed to teams in the development of large proteins, small peptides, enzyme replacement therapeutics, and small molecules and oligo conjugates. I have also successfully contributed to key bioanalytical needs for the approval of Vimizim for the treatment of Morquio Syndrome and Pegvaliase for the treatment of phenylketonuria. Most recently I am focused in a new generation drug class field in antibody oligonucleotides conjugates in support of muscular rare diseases as the current immunogenicity lead for both pre clinical and clinical lead drug candidates. In addition to method development transfers and validation, I’ve worked extensively with CROs, vendors, SMEs throughout the drug development and research field.